Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
March 05, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
February 13, 2024 16:30 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
January 18, 2024 17:00 ET
|
Axogen, Inc.
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve...
BCLI FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm – BCLI
January 01, 2024 13:55 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between...
Axogen Announces Transition of Finance Team Leadership
December 06, 2023 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
November 26, 2023 21:36 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI)...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
November 19, 2023 23:19 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
November 16, 2023 19:49 ET
|
Polaris Group
TAIPEI, Taiwan and SAN DIGEO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the Company has initiated the rolling submission of its Biologic License...
OTLK INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
November 16, 2023 14:09 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
Axogen, Inc. Reports 2023 Third Quarter Financial Results
November 07, 2023 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...